An Introduction to Dermatological Cancer
The past decade has seen significant advances in the treatment landscape of melanoma. Therapies targeting the BRAF oncoprotein pathway and the development of immunotherapies have transformed the standard of care for patients.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Dermatological Cancer Content
Dermatitis management and chlormethine gel: new key learning points
Watch this symposium discussing contact dermatitis management in MF-CTCL. Filmed during the 4th World Congress of Cutaneous Lymphomas on February 12, 2020 in Barcelona, Spain. Watch the symposium presentation from Dr Brian Poligone Watch Now
- Understand current US clinical practice in the management of MF-CTCL
- Understand the optimal use of chlormethine gel in this treatment setting
- Manage contact dermatitis in MF-CTCL patients treated with chlormethine gel
A patient’s journey through the immuno-oncology treatment landscape in melanoma
Watch leading experts explore the impact of immunotherapy incorporating PD-1 blockade on the treatment landscape and patient experience in melanoma.
- Discuss factors to consider when selecting PD-1 inhibitors to treat melanoma
- Understand the rationale for combination regimens incorporating PD-1 blockade
- Analyse the role of long-term clinical and real-world data in informing treatment decisions
Paolo A Ascierto,ESMO 2020 – The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study
Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study. Questions What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic […]
Ana Maria Arance Fernandez, ESMO 2020 – Lenvatinib plus Pembrolizumab for Advanced Melanoma: Initial Results of LEAP-004
touchONCOLOGY meets with Dr Ana Maria Arance Fernandez at ESMO 2020 to discuss findings from the LEAP-004 trial, and the role lenvatinib plus pembrolizumab can play in the treatment of advanced melanoma. The late-breaking abstract ‘Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of […]
BRAF-mutant Melanoma – The COLUMBUS Trial
European Oncology & Haematology. 2018;14(2):78–9 DOI: https://doi.org/10.17925/EOH.2018.14.2.78
Melanoma represents a significant and increasing public health burden, and is the largest cause of skin cancer-related deaths.1 Approximately half of advanced (unresectable or metastatic) melanomas have a mutation in the BRAF gene, with V600E being the most common mutation, leading to the therapeutic use of BRAF inhibitors.2 However, the response rates with single-agent BRAF […]
Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma
In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma. Questions: 1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European approval of encoranefib plus binimetanib for BRAF-mutant metastatic melanoma? (0:11) […]
Paolo A Ascierto, ESMO 2018 – Developments in the Treatment of Advanced Melanoma
touchONCOLOGY met with editorial board member Dr Paolo Ascierto at ESMO 2018 to discuss the recent developments in the treatment of advanced melanoma. In this expert interview, Dr Ascierto reviews some of the recent trials investigating various immunotherapy combinations, and how survival rates have increased over the last few years. However, the levels of toxicity […]
Jeffrey S Weber, ASCO 2018 – Resected Stage III Melanoma and the CheckMate 238 Trial
touchONCOLOGY talks to Jeffrey S Weber from the Laura and Isaac Perlmutter Cancer Cente and NYU Langone Medical Center about the limitations of ipilimumab for the treatment of resected stage III melanoma and how the findings of the CheckMate238 trial can improve the safety profile of this patient population. 1. What are the limitations of […]
Paolo Ascierto, ASCO 2018 – Personalised strategies and advances in the treatment of melanoma
Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment. 1. How are personalised strategies impacting the treatment of melanoma? (0:11) 2. What molecular markers have been validated to inform selection of therapy? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!